Vascular endothelial cells respond to environment and cellular stimuli with profound changes of adhesive and inflammatory phenotypes (4, 12) . This process of endothelial cell activation results in release of inflammatory and chemotactic cytokines and enhanced leukocyte recruitment via expression of adhesion molecules (12) . During infection, the activated endothelial cells also play a pivotal role in the increased leukocyte-endothelial cell interaction and initiation of host inflammatory responses (4) . The recruitment of subsets of leukocytes into inflamed tissues is an important process for the appropriate immune responses and host defense. In particular, the macrophages in pathological foci play a central role in the inflammatory responses through their ability to produce various mediators. Although the mechanism of monocyte infiltration is not yet fully understood, macrophage chemoattractant protein 1 (MCP-1) is thought to play a significant role (34) . MCP-1 is a member of the CC subfamily of the chemokine family and attracts both monocytes and lymphocytes (2, 35, 55) . Various types of cells such as endothelial cells and macrophages are known to produce MCP-1 in response to diverse stimuli, including proinflammatory cytokines and pathological microorganisms (11, 17, 18, 41, 55) . In addition, high levels of MCP-1 mRNA were found in pathological foci of atherosclerosis, glomerulonephritis, and rheumatoid arthritis (48, 59, 65) . The patterns of stimulus-induced MCP-1 mRNA expression, however, vary with each cell type or stimulus. Modulation of MCP-1 synthesis may provide a means to suppress cellular recruitment in these pathological conditions, as well as a variety of other inflammatory diseases.
Multiple signaling mechanisms have been reported to be involved in the intracellular activation of MCP-1 gene expression in vascular endothelial cells by a various stimuli (27, 31, 43, 52) . Diverse signal transduction pathways, including activation of phosphatidylinositol-3-OH kinase, Akt/protein kinase B (43) , phospholipase C (27), p60src-Ras (31) , protein kinase C, and tyrosine kinases (52) , are involved in the expression of the MCP-1 gene in response to a variety of extracellular stimuli such as cytokines, mitogens, and shear stress. Some of the pathways are probably activated concomitantly or selectively according to the stimulating agents (27, 52) . Subsequently, signals from these stimuli may be transmitted to the nucleus through the activation of mitogen-activated protein (MAP) kinases (46) and transcription factors such as NF-B or AP-1 (21, 25, 63, 64) . The involvement of MAP kinase pathways in the regulation of the MCP-1 expression has been reported in endothelial cells in response to various stimulating agents (6, 28, 31, 39, 51) . Additionally, the MAP kinase pathways were also selectively activated according to the stimuli (15, 28, 39) . The activated MAP kinase pathways have been suggested to be closely involved in the transcriptional regulations mediated by transcription factors, Activator protein 1 (AP-1) (6, 38, 64) or NF-B (5, 63) . The promoter region of the human MCP-1 gene has been shown to contain putative consensus binding sites for a variety of transcription factors (54) . The triphorbol acetate response elements (TRE), which is recognized by the AP-1 transcription heterodimer c-Jun and c-Fos and/or NF-B sites upstream of the transcription start site are involved in the regulation of MCP-1 gene induction in various cells types in responses to diverse extracellular stimuli (37, 51, 54) . It has been suggested that the differential activation and binding of inducible transcription factors such as AP-1 and NF-B to the promoter regions of chemokine genes provides a critical regulatory mechanism by which the chemokine can be selectively expressed in a cell type-specific and stimulusspecific manner (47) .
Although a number of molecular studies have identified the signal transduction pathways and the cis-regulatory elements and trans-acting factors in the expression of MCP-1 gene in endothelial cells, the intracellular signaling pathways that couple endothelial activation from receptor levels to the level of MCP-1 expression are so far only poorly understood. Especially, little is known about the role of the different MAP kinase cascades and the subsequent activation of transcription factors involved in the transcriptional regulation of MCP-1 in response to infectious agents.
Orientia tsutsugamushi is the causative agent of scrub typhus, which is characterized by eschar, rashes, and other inflamed organs where dense collections of mononuclear cells, including lymphocytes and macrophages, are found around the vasculatures (1). The extent of infiltrating leukocytes around the blood vessels is closely related with the clinical manifestation of scrub typhus (1, 9, 62) . Previously, we have reported that subsets of chemokine genes were produced in macrophages and endothelial cells infected with O. tsutsugamushi (10, 11) . Among the chemokine genes expressed, mononuclear cell-specific chemokine MCP-1 was highly up-regulated in both types of cells infected with O. tsutsugamushi. Furthermore, we have suggested that the induction of MCP-1 might be mediated by an NF-B-independent mechanism and the activation of AP-1 is possibly involved in the expression of the chemokine genes in human transformed microvascular endothelial cell (HMEC) line HMEC-1 infected with O. tsutsugamushi (10) . In this work, we have analyzed the functional role of the two transcription factors, AP-1 and NF-B, in MCP-1 transcription in human umbilical vein endothelial cells (HUVEC) infected with O. tsutsugamushi. By using the inhibitors which block the activation of NF-B or inhibit the activation of AP-1 through blocking the specific MAP kinases, the involvement of the signal transduction pathways in the induction of the MCP-1 gene was investigated. In addition, we have performed the functional analysis of the putative binding sites for AP-1 or NF-B located in the proximal promoter region or enhancer region of MCP-1 gene by using a transient-transfection approach in HUVEC.
MATERIALS AND METHODS
Cell culture. HUVEC were obtained by collagenase digestion of umbilical veins as previously described (26) . The isolated HUVEC were cultured in M199 medium (Life Technologies, Grand Island, N.Y.), containing 20% fetal bovine serum, 2 mM L-glutamine, endothelial cell growth supplement (30 g/ml; Sigma Chemical Co., St. Louis, Mo.), penicillin (100 U/ml), and streptomycin (100 g/ml). Endothelial cells were identified by cobblestone appearance and specific staining for Von Willebrand factor (DAKO Co., Carpinteria, Calif.). HUVEC from between passages 3 and 6 were used for the experiments.
Preparation of O. tsutsugamushi inoculum. O. tsutsugamushi Karp (American Type Culture Collection, Manassas, Va.) was propagated in monolayers of L929 cells as described previously (11) . The titer of infectivity of the inoculum was determined as described previously (11) . A total of 1.4 ϫ 10 7 infected-cell counting units of O. tsutsugamushi was used to infect endothelial cells for the preparation of total RNA and nuclear extract. The L929 cell lysate was prepared as described above and was used in infection of endothelial cells for the control experiments.
Stimulation of cells. Endothelial cells were seeded onto 100-mm-diameter dishes (Becton Dickinson Labware, Franklin Lakes, N.J.) for the preparation of total RNA or for the preparation of nuclear extract. Total RNA was isolated at 0, 0.5, 1, 3, 6, 12, and 24 h after infection of O. tsutsugamushi. Nuclear protein extracts were prepared at 0, 0.25, 0.5, 1, 4, and 8 h after infection. In the inhibition assays, endothelial cells were preincubated with 50 M pyrrolidinedithiocarbamate (PDTC) (Sigma Chemical Co.), 100 M N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) (Sigma Chemical Co.), and various concentrations of SB 203580 (Sigma Chemical Co.) and PD 098059 (Sigma Chemical Co.) for 1 h before O. tsutsugamushi was inoculated. The inhibitors were maintained during the course of inhibition assays.
RNase protection assay. Total RNA was prepared with an RNeasy kit (Qiagen GmbH, Hilden, Germany) as specified by the manufacturer and was quantified spectrophotometrically. Detection and semiquantification of various human chemokine mRNAs was performed with a multiprobe RNase protection assay system from Pharmingen (San Diego, Calif.) as described previously (10) . Nucleaseprotected RNA fragments were resolved on a 5% polyacrylamide sequencing gel. The bands were observed after autoradiography. The band intensities shown in autoradiography were digitized by scanning the images and analyzed with TINA software (Raytest Isotopenmeßgeräte GmbH, Straubenhardt, Germany). The densitometric intensity was normalized with respect to the intensities of the band for the housekeeping gene, the glyceraldehyde-3-phosphate dehydrogenase gene.
Reverse transcription (RT)-PCR. HUVEC were plated onto six-well dishes and allowed to reach confluence. Then, cells were infected with O. tsutsugamushi for 3 h in the absence or presence of inhibitors of AP-1 activation. The medium was removed from each well, and total RNA was extracted from the cells using an RNeasy kit. cDNA synthesis was conducted using 10 U of avian myeloblastosis virus reverse transcriptase (Promega, Madison, Wis.) and 200 ng of oligo(dT) primer (Promega), together with manufacturer's buffer, 20 nmol of deoxynucleoside triphosphate, and 12.5 nmol of MgSO 4 for 1 h at 42°C. PCR amplification consisted of 25 cycles of 30 s of denaturation at 94°C, 30 s of annealing at 58°C (MCP-1) or 55°C (␤-actin), and extension at 72°C for 1 min as described previously (11) . The sequences of primers used for the amplifications and the size of PCR products were as follows: MCP-1 (135 bp), 5Ј-AAT GCC CCA GTC ACC TGC TGC TAT-3Ј and 5Ј-TCT CCT TGG CCA CAA TGG TCT TGA-3Ј; ␤-actin (349 bp), 5Ј-TGG AAT CCT GTG GCA TCC ATG AAA C-3Ј and 5Ј-TAA AAC GCA GCT CAG TAA CAG TCC G-3Ј. The amplified DNA fragments were resolved in 1.2% agarose gels, and the densities of the DNA bands were analyzed as described previously (11) . The densitometric intensity was normalized by comparing the ratio of MCP-1 bands with that of ␤-actin.
Nuclear extraction and EMSA. Electrophoretic mobility shift assays (EMSA) were performed as described previously (10) . Equal amounts of nuclear extracts (10 g of protein) from each sample were incubated for 30 min at 25°C in 20 l of binding buffer [10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.5 mM dithiothreitol,extracts with NF-B or AP-1 probe, a competition assay was performed with a 50-fold molar excess of unlabeled oligonucleotides. Nuclear translocation of the NF-B heterodimer was analyzed by a supershift assay with anti-p65 antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.). The nuclear extracts were mixed with 1 g of anti-p65 antibody and were hybridized with the NF-B-specific oligonucleotide probe. The supershifted bands were analyzed after separation on 5% nondenaturing polyacrylamide gels and autoradiography.
Construction of plasmid. The plasmid pGL3-basic (Promega) was used to construct MCP-1-luciferase hybrids. To obtain pMCP560, pMCP121, pMCP90, pMCP73, pMCP65, and pMCP62, DNA fragments covering position Ϫ560 to ϩ43, position Ϫ121 to ϩ43, position Ϫ90 to ϩ43, position Ϫ73 to ϩ43, position Ϫ65 to ϩ43, and position Ϫ62 to ϩ43 were amplified by using the standard PCR technique with chemically synthesized primers that corresponded to nucleotides Ϫ560 to Ϫ537 of the sense strand, 5ЈGGG ACG CGT CCT ACA GTT CTG CTA GGC TTC TA3Ј; Ϫ121 to Ϫ98 of the sense strand, 5ЈGGG ACG CGT CAG CAG ATT TAA CAG CCC ACT TA3Ј; Ϫ90 to Ϫ69 of the sense strand, 5ЈGGG ACG CGT GGA AGA TCC CTC CTC CTG CTT3Ј; Ϫ73 to Ϫ53 of the sense strand, 5ЈGGG ACG CGT GCT TGA CTC CGC CCT CTC TC3Ј; Ϫ65 to Ϫ46 of the sense strand, 5ЈGGG ACG CGT CCG CCC TCT CTC CCT CTG C3Ј; Ϫ62 to Ϫ43 of the sense strand, 5ЈGGG ACG CGT GCC CTC TCT CCC TCT GCC CG3Ј; and ϩ20 to ϩ40 of the antisense strand, 5ЈGAA GAT CTG AGC TTC AGT TTG AGA ATT GGA TG3Ј. MluI or BglII linkers were incorporated in the 5Ј end of these oligonucleotides. Human genomic DNA was isolated from HUVEC and was used as the PCR template. PCR products were digested with MluI and BglII and then cloned into the MluI-BglII site of the pGL3-basic plasmid. To obtain pMCP560-En, the DNA sequence from position Ϫ2805 to Ϫ2787 of the sense strand, 5ЈGGG GTA CCT TGT GTG TCC CCA AGC G3Ј and position Ϫ2101 to Ϫ2081 of the antisense strand, 5ЈGGG AGC TCG TGC ATC CTT TAC CAT GAA CT3Ј. KpnI or SacI linkers were incorporated in the 5Ј end of these oligonucleotides. The amplified DNA was then digested with KpnI and SacI and cloned into the KpnI-SacI site of the pMCP560. The orientation of the positive clone was determined by DNA sequencing. Site-directed mutagenesis was performed by using a method previously reported (29) . Two-step PCRs were conducted. The primers used are as follows: MA1 primer pair (position Ϫ2650 to Ϫ2627), 5ЈACG GGA TCT aGa gAC TTC CAA AGC3Ј; MA2 primer pair (position Ϫ2616 to Ϫ2591), 5ЈGAG TGG GAA TTc ggA CTC ACT TCT CT3Ј; and MA3 primer pair (position Ϫ2282 to Ϫ2259), 5ЈAAC AAG TGA Gga gTG CCA CAG GAT3Ј. Mutated bases are designated by lowercase letters. The resulting mutated DNA fragments were cloned into the KpnI-SacI site of the pMCP560 to yield pMCP560-EnMA1, pMCP560-EnMA2, pMCP560-EnMA3, pMCP560-EnMA4, and pMCP560-EnMA5.
Cell transfection and luciferase assay. HUVEC were transfected using Lipofectin (Life Technologies) as specified by manufacturer. Briefly, cells of 50 to 60% confluent monolayers were washed with OPTI-MEM I reduced serum medium (Life Technologies) and incubated with combined solution containing 10 l of Lipofectin and 3 g of reporter plasmid for 3 h in six-well culture. After incubation, the DNA-containing medium was replaced with culture medium and cells were further incubated for 18 h before infection with O. tsutsugamushi. Following stimulation, the cells were washed once with phosphate-buffered saline and lysed with 100 l of reporter lysis buffer (Promega). The luciferase activity of lysed cells was determined using a luciferase assay system (Promega) and immediately analyzed for light production in a TD-20/20 luminometer (Turner designs, Sunnyvale, Calif.). Transfection efficiencies were monitored and normalized by cotransfection of a pCMV-␤gal vector (1 g) for ␤-galactosidase (19) .
RESULTS
MCP-1 mRNA expression was increased by O. tsutsugamushi. Before and after exposure of HUVEC to O. tsutsugamushi, the chemokine transcript levels were assayed at various time points with RNase protection assays (Fig. 1A) . Figure 1 represents the result of three separate experiments. Basal levels of MCP-1 and interleukin-8 (IL-8) messages were detected in the uninfected cells. The levels of the transcripts for MCP-1 and IL-8 increased as early as 30 min after infection, with peak responses at 3 and 1 h, respectively. While the transcripts for MCP-1 were sustained for 6 h after infection, the RNA messages for IL-8 persisted for 1 h after infection. The transcripts for RANTES and IP-10 were also detectable at 6 h after infection in HUVEC. The levels of transcripts for RANTES and IP-10 were significantly lower than those of MCP-1 and IL-8 and were gradually increased by 48 h after infection. To confirm the induction of the MCP-1 gene, semiquantitative RT-PCR was performed at various time points after infection with O. tsutsugamushi (Fig. 1B and C) . A similar result was obtained from the RT-PCR analysis. The normalized levels of MCP-1 gene at 3 and 6 h after infection were increased by Effect of the inhibitors of NF-B activation on the expression of MCP-1 mRNA. In order to examine whether NF-B activation is involved in MCP-1 expression of O. tsutsugamushiexposed HUVEC, we used two inhibitors of NF-B activation, the antioxidant PDTC (3, 42) and the proteasome inhibitor TPCK (3, 13, 36) . Interestingly, when the endothelial cells were incubated with O. tsutsugamushi in the presence of 50 M PDTC or 100 M TPCK, induction of MCP-1 and IL-8 was not significantly affected in HUVEC (Fig. 3A) . Rather, the level of MCP-1 was increased by approximately 15% in cells infected with O. tsutsugamushi in the presence of PDTC compared to that of cells infected with O. tsutsugamushi alone. The results were reproduced in three separate trials. We, therefore, have investigated whether the activation of NF-B is affected by the inhibitors in HUVEC infected with O. tsutsugamushi (Fig. 3B) . Although the basal levels of NF-B complexes were detected in the cells treated with medium or L-cell lysate, the activation and nuclear translocation of NF-B was increased when stimulated with O. tsutsugamushi. In the presence of the inhibitors of NF-B activation, the levels of NF-B complex were remarkably decreased and comparable to those of control groups. The proteasome inhibitor, TPCK, was more effective in inhibiting NF-B activation than PDTC. These results showed that the inhibitors in the concentrations used were effective in inhibiting the activation and nuclear translocation of NF-B. The specificity of the activated NF-B and DNA complexes were demonstrated by supershift assay using antip65 antibody (Fig. 3B) .
Effect of the inhibitors of AP-1 activation on the expression of MCP-1 mRNA. Since infection of O. tsutsugamushi also caused an increase in AP-1 DNA-binding activity, the roles of the MAP kinase pathways able to activate this transcription factor complex were examined using specific inhibitors of MAP kinase pathways. The compound PD 098059 selectively blocks activation of the extracellular signal-related kinase (ERK) kinase MEK1, which in turn prevents activation of ERK1/2 (16), whereas SB 203580 specifically inhibits p38/CSBP kinase activities (33) . HUVEC were pretreated with PD 098059 or SB 203580 and thereafter infected with O. tsutsugamushi. As shown in Fig. 4 tsutsugamushi-infected HUVEC. These MAP kinase pathwayrelated kinases modulate regulation of AP-1 activity through phosphorylation (64) . In addition, recent studies have suggested that the p38 MAP kinase pathway may be involved in the activation of NF-B (5, 63). We therefore investigated the effect of the inhibitors on O. tsutsugamushi-induced AP-1 and NF-B activation in HUVEC (Fig. 5 ). HUVEC were treated with PD 098059 (25 M) or SB 203580 (25 M) and subsequently infected with O. tsutsugamushi for 1 h. As shown in Fig.  5A , both PD098059 and SB203580 significantly inhibited the O. tsutsugamushi-induced activation of AP-1, as determined by EMSA. In an identical nuclear extract used in AP-1 studies, it was found that PD 098059 and SB 203580 were not able to prevent O. tsutsugamushi-induced NF-B-DNA binding activity (Fig. 5B) , suggesting that inhibition of the MAP kinase pathways did not interfere with release of NF-B from IB. 
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Functional analysis of MCP-1 gene regulation. To elucidate the mechanism of MCP-1 transcriptional regulation in HUVEC infected with O. tsutsugamushi, the enhancer region (base Ϫ2805 to Ϫ2081) and proximal promoter region (base Ϫ560 to ϩ43) were cloned into a luciferase reporter plasmid (54) . The human MCP-1 gene contains two NF-B binding sites in an enhancer region (A1 and A2) and one site (A3) in the proximal promoter region. The AP-1 binding site (TRE) is also located in the enhancer region (P1) and in the proximal promoter region (P2 and P3). To investigate which regions are involved in the transcriptional activity of MCP-1 in HUVEC by O. tsutsugamushi, a series of progressive 5Ј-deletion constructs were generated (Fig. 6A) . These constructs were used to transfect HUVEC transiently and then assayed for luciferase activity in the presence or absence of O. tsutsugamushi. As seen in Fig. 6B , HUVEC transfected with pMCP560-En demonstrated a significant increase in luciferase activity at 24 h after infection with O. tsutsugamushi. The induced levels of luciferase activity were twofold to threefold greater than that of uninfected cells. Deletion of the enhancer region resulted in a significant reduction in response to O. tsutsugamushi as well as a basal level of luciferase activity, although the luciferase activities inducible by O. tsutsugamushi were showed in the absence of enhancer region. The deletion of the upstream region of the proximal promoter (position Ϫ121 to Ϫ560), P2, and A3 did not affect the basal activity and inducible activity of the luciferase gene in response to O. tsutsugamushi infection (Fig. 6B) . However, deletion of P3 decreased both basal levels and inducibility of the luciferase gene. Further deletion of the GC box significantly reduced basal and inducible levels.
Next, we further investigated whether the two B-binding sites and a TRE are required for the maximal O. tsutsugamushi induction of the MCP-1 promoter, HUVEC were transfected with plasmids containing mutations in the specific binding sites. A series of mutant constructs were generated (Fig. 7A ) and analyzed by transient transfection in HUVEC (Fig. 7B) . Site-directed mutagenesis of the B-binding site located at tsutsugamushi. pMCP560-EnMA2, which has a mutation at another B-binding site (position Ϫ2612 to Ϫ2603 bp), and pMCP560-EnMA3, which has a mutation at TRE (position Ϫ2276 to Ϫ2270), also showed reduced induction of luciferase activity, with a reduction of 50% compared with pMCP560-En. Mutations in all the binding sites also resulted in a decrease in the amount of O. tsutsugamushi-induced luciferase activity. These mutations were not significantly affected the transcriptional activity of uninfected cell.
DISCUSSION
In human endothelial cells, the regulation of MCP-1 expression has been studied intensively (27, 37, 45, 61) . The expression of the MCP-1 gene is controlled in a stimulus-specific manner and involves differential activation of the redox-responsive transcription factors, AP-1 and NF-B (6, 10, 37, 39, 40) . Inflammatory cytokines, including IL-1 and tumor necrosis factor alpha (TNF-␣), activate NF-B and AP-1 and induce the expression of the MCP-1 gene in endothelial cells (37) . Induction of the chemokine by infectious pathogens such as Chlamydia pneumoniae or Borrelia burgdorferi also requires the activation NF-B (17, 40) . Membrane microparticles produced by platelets or leukocytes, however, do not activated NF-B, and the production of MCP-1 may be mediated by the activation of AP-1 in HUVEC (39) . Previously, we have also reported that the expression of MCP-1 by O. tsutsugamushi might be independent of the activation of NF-B and was probably mediated by activation of AP-1 in human microvascular endothelial cell line (10) . In this report, we have showed that the induction of MCP-1 by O. tsutsugamushi was not blocked by the inhibitors of NF-B activation, although the transcription factor was activated by the stimulation of O. tsutsugamushi and the activation of NF-B was blocked by the inhibitors used in HUVEC (Fig. 3) . The levels and kinetics of chemokine transcription were slightly different in the two types of endothelial cells, HUVEC and HMEC (10) . The levels of mRNAs for MCP-1 and IL-8 were more highly induced in HUVEC than those in HMEC-1. And the induction of IP-10 mRNAs was barely detectable in HMEC-1. These differences in the induction of chemokine genes might be due to phenotypic heterogeneity between the transformed microvascular endothelial cells and the primary macrovascular endothelial cells. It has been reported that the microvascular endothelial cells are different from macrovascular endothelial cells in many ways (4, 10, 12, 17, 18) . The different levels and kinetics of the transcriptional factor activation (NF-B and AP-1) could also partly explain the different chemokine expression in two types of endothelial cells (10) . Although the antioxidant PDTC has been known to increase the DNA-binding activity of AP-1, it inhibits the induction of IL-8, IL-6, and granulocyte-macrophage colony-stimulating factor in a dose-dependent manner by preventing the induction of NF-B DNA-binding activity by TNF-␣ (42). The proteasome inhibitors such as TPCK also block NF-B translocation to the nucleus and the induction of Another transcription factor, AP-1, was also activated as early as 15 min after stimulation in endothelial cells infected with O. tsutsugamushi, and the kinetics of AP-1 activation was well correlated with the induction of MCP-1 gene (Fig. 2B) . We, therefore, have tested the effect of the two inhibitors blocking the MAP kinase pathways on the expression on the transcription of MCP-1 gene. There are at least three main groups of MAP kinases: ERK, c-Jun N-terminal kinase (JNK), and p38 (46, 64) . In general, the ERKs are strongly activated on stimulation of cells with mitogens such as epidermal growth factor, platelet-derived growth factor, serum, and phorbol-myristate acetate through sequential activation of the upstream kinases Raf and MEK. In contrast to the ERKs, two other subgroups of the MAP kinase family, namely, the p38 and the JNK subgroups, are only weakly activated by mitogens but are highly stimulated on exposure to inflammatory cytokines such as TNF-␣ and IL-1 and a wide variety of environmental stress inducers such as lipopolysaccharides. The upstream activator of p38 is the dual specificity kinase MKK6, whereas JNK is activated by MKK4/SEK. These members of the MAP kinase family have been reported to regulate the activation of AP-1 (64) . The involvement of the MAP kinase pathways and the transcription factor AP-1 in the regulation of MCP-1 gene in endothelial cells has been tested using the specific inhibitors (15, 38, 53) . The transcription of MCP-1 is inhibited by the p38 MAP kinase inhibitor, SB 203580, in endothelial cells stimulated by homocysteine (53) or by the ERK inhibitor, PD 098059, in cells activated by vascular endothelial cell growth factor (38) . In HUVEC interacted with activated platelets, the secretion of MCP-1 and monocyte-endothelium adhesion was reduced by SB 203580, but not by PD 098059 (15) . These selective activations of the MAP kinase pathway according to the stimulating agents could partly explain the differential regulation of the chemokine gene in endothelial cells. When the MAP kinase inhibitors PD 098059 and SB 203580 were treated in HUVEC, the levels of O. tsutsugamushi-induced MCP-1 transcripts were reduced in a dose-dependent manner (Fig. 4) . In addition, the activation of AP-1 induced by O. tsutsugamushi infection was significantly suppressed by the treatment of the inhibitors (Fig. 5A) . These results demonstrated that the activation of ERK and p38 MAP kinases is necessary for both the activation of AP-1 and MCP-1 induction by O. tsutsugamushi, but the p38 MAP kinase pathway has a more potent effect on the transcriptional regulation of the gene. In agreement with previous reports indicating that this signaling pathway is required for the activation of AP-1 (64), we have shown that O. tsutsugamushi induction of AP-1 requires activation of the ERK and p38 MAP kinases pathways. Therefore, the effect of PD 098059 and SB 203580 on MCP-1 mRNA (Fig. 4) is probably due in part a decrease in the abundance of the AP-1 components c-Fos and c-Jun. Because there is no available specific inhibitor for JNK pathway, we could not investigate the involvement of the JNK pathway in the activation of AP-1 and induction of MCP-1 in response to O. tsutsugamushi infection. We also studied the MAP kinase pathways, as recent studies have suggested their involvement in the regulation of NF-B In the functional analysis of the MCP-1 promoter region, however, B-binding sites in the enhancer region were required for the induction of reporter luciferase activity by O. tsutsugamushi infection (Fig. 7) . This functional analysis was originated from the assay performed by Ueda et al. (54) . They have suggested that the B-binding site located between bp Ϫ2612 and Ϫ2603 was important for cytokines or mitogeninduced enhancer activity in diverse types of cells. Recently, Goebeler et al. have also reported that the mutations in the B-binding sites in the enhancer region resulted in complete loss of promoter inducibility in HUVEC stimulated with NiCl 2 (27) . They have suggested that MCP-1 induction in endothelial cells requires activation of the IKK␤/IB␣/NF-B signaling pathway, resulting in nuclear accumulation of p65 and subsequent recruitment of cofactors, and proper assembly and activity of this transcriptional complex is further modulated by the p38 MAP kinase cascade and a phospholipase C-dependent pathway (27) . It seems likely that multiple signaling pathways are activated in endothelial cells stimulated with environmental stresses and the activation of endothelial cells is modulated by the different sets of transcription factors activated by the signaling pathways. Here, we found that the Bbinding site in the enhancer region of MCP-1 gene was important for the inducible induction of MCP-1 by O. tsutsugamushi infection, although AP-1 binding sites in proximal promoter region (position Ϫ69 to Ϫ63) and enhancer region (position Ϫ2276 to Ϫ2270) were also required for the inducible expression of MCP-1 in HUVEC. The requirement of the B-binding site for the inducible expression of MCP-1 might be contrary to the effects of the inhibitors of NF-B activation. We have tried to investigate the effect of the inhibitors on the reporter gene expression using transient-transfection assay, but the viability of HUVEC was markedly reduced by the chemicals used after transfection, and it was very difficult to assay the effect of the inhibitors. However, these conflicting results could be explained partly by the fact that the transcriptional regulation in promoter regions of many genes integrated in chromosome is different from those of the genes used in transient transfection assays (14, 22, 49, 56, 60) . Alteration of chromatin structures by histone modification and subsequent formation of appropriate transcriptional complex are required in the transcriptional activation (8) . Recently, some reports have also suggested that histone acetyltransferase activity of cyclic AMP-responsive element binding protein-binding protein or the activation of TFIID are required for the formation of active transcription complex in NF-B-dependent transcription (7, 50, 58) . In the case of the transcriptional regulation of MCP-1 gene, the chromatin structure is also one of the important regulatory mechanisms for the expression of the gene (20) . Furthermore, transcriptional coactivators such as p300 or p90 may be involved in the formation of active enhanceosome formation in the NF-B-mediated transcriptional regulation of MCP-1 gene (23, 27) . Hence, appropriate nucleosomal structure is probably the reason why transient transfections of reporter gene construct harboring the promoter region resulted in a different effect of the transcription factor, NF-B, although the possible involvement of activated NF-B in the expression of MCP-1 gene could not be excluded thoroughly in endothelial cells infected with O. tsutsugamushi. Interestingly, the role of AP-1 in the alteration of the nucleosome is suggested to be critical in the transcriptional activation (44). Ng et al. have reported that the binding of Fos/Jun to a single high-affinity site incorporated into an acetylated nucleosome resulted in the complete disruption of nucleosomal structure without histone displacement, and this disruption was sufficient to facilitate the subsequent binding of a second transcription factor (44) . In conclusion, for the first time, we have reported that the expression of the MCP-1 gene in human endothelial cells infected with the intracellular bacterium O. tsutsugamushi is primarily affected by MAP kinase pathways, leading to the activation of AP-1, although it remains to be determined how the activation of NF-B affects the transcription of MCP-1. Previously, we have also reported that the induction of MCP-1 in HMEC-1 might be an NF-B-independent mechanism, probably mediated by the activation of AP-1 (10). Our present results suggest that the activation of AP-1 by O. tsutsugamushi infection might play a pivotal role in the activation of endothelial cells and the transcriptional induction of inflammatory genes such as MCP-1 and suggest that the activation of endothelial cells by O. tsutsugamushi is mediated by signaling pathways different from those that mediate other environmental stimuli. These differences resell in the differential activation of signal transduction pathways and transcription factors and thus the differential inflammatory responses.
